UOC Malattie Infettive, PO "S.S. Annunziata", Azienda Ospedaliera di Cosenza, Italy.
UOC Farmacia Ospedaliera, PO "Annunziata", Azienda Ospedaliera di Cosenza, Italy.
Recenti Prog Med. 2021 Apr;112(4):311-314. doi: 10.1701/3584.35690.
Ivabradine is a pure heart rate-lowering drug that acts directly on the sinus node and does not affect atrioventricular or intraventricular conduction times, myocardial contractility or ventricular repolarization. Ivabradine is used in the treatment of adults with New York Heart Association (NYHA) class II-IV chronic heart failure (CHF) with systolic dysfunction, in sinus rhythm, with a heart rate of ≥75 beats per minute (bpm). This report describes the beneficial effect of ivabradine on clinical parameters in a HIV-infected patient with dilated cardiomyopathy presenting with NYHA class III CHF symptoms. Ivabradine improved functional capacity and left ventricular (LV) systolic function in our patient with HIV-related dilated cardiomyopathy and CHF. This report also lists the summaries of potential clinically significant interaction, likely to require additional monitoring, alteration of drug dosage or timing of administration, between ivabradine and antiretroviral drugs.
伊伐布雷定是一种纯心率降低药物,直接作用于窦房结,不影响房室或室内传导时间、心肌收缩力或心室复极。伊伐布雷定用于治疗纽约心脏病协会(NYHA)心功能 II-IV 级慢性心力衰竭(CHF)伴有收缩功能障碍、窦性心律、心率≥75 次/分钟(bpm)的成年人。本报告描述了伊伐布雷定对一名患有扩张型心肌病、NYHA 心功能 III 级 CHF 症状的 HIV 感染患者临床参数的有益影响。伊伐布雷定改善了我们这位 HIV 相关扩张型心肌病和 CHF 患者的功能能力和左心室(LV)收缩功能。本报告还列出了伊伐布雷定和抗逆转录病毒药物之间可能存在的具有临床意义的潜在相互作用的摘要,这些相互作用可能需要额外的监测、改变药物剂量或给药时间。